genetic marker, assessment of biochemical markers have not lowered the rate of PTL 12 . A wide range of tocolytics have been utilized for the management of PTL already mentioned. Debate is going on which tocolytic is the best? There is little reliable information about current clinical practice but it is likely that ritodrine hydrochloride, a beta-agonist, remains the most widely used tocolytic . Magnesium sulphate is popular for tocolysis in the USA and some other parts of the world, but is rarely used for this indication in the UK 13 . There is growing interest in calcium channel blockers as a potentially effective and well tolerated form of tocolysis 14 .
Types of Tocolytic
Calcium channel blockers (CCB) -These agents interfere with the calcium ions transfer through the myometrial cell membrane. They decrease intracellular free calcium concentration and induce myometrial relaxation [15] [16] [17] . When tocolysis is indicated for women in preterm labour, calcium channel blockers are preferable to other tocolytic agents compared, mainly beta-agonists 18 . Nifedipine is used most commonly and is very popular to the obstetrician. Numerous RCTs have shown them to be effective as Beta-agonist and Magnesium sulphate and Atosiban. A comperative study showed that CCB have fewer maternal side effects than other tocolytics and have no adverse effects on foetal outcome 15 . In general patients may complain of headache, dizziness, tachycardia, palpitations, flushing, and nausea. Continuous monitoring of the fetal heart rate is recommended as transient hypotension may occur but it is reversible. In 2002 meta analysis of 12 RCT n==1029, concluded that nifedipine is more effective than B agonist and clearly proved to be superior. The investigators found a reduced risk of delivery within 7 days and at less than 34 weeks' gestation. Cessation of treatment due to adverse reaction occurred in 1 of 419 patients, vs 29 of 414 with other tocolytics 16 . The nifedipine-treated neonates also had decreased risk of respiratory distress syndrome, necrotizing enterocolitis, and intraventricular hemorrhage 17 .
The recommended protocol consists of 20 mg orally stat, followed by 20 mg orally after 30 minutes if contractions persist, followed by 20 mg orally every 3-8 hours for 48-72 hours as indicated. The maximum dose is 160 mg/day. After 72 hours, if maintenance is required, patients can be changed to long-acting nifedipine 30-60 mg daily. Contraindications include allergy to nifedipine, hypotension, hepatic dysfunction, concurrent use of beta-agonists, transdermal nitrates, or other antihypertensive medication 18 . Hypotension can occur with concurrent use of nifedipine and magnesium. Hypotension is a side effect; however, it is minimal in normotensive patients 19 . Continuous monitoring of the fetal heart rate is recommended as long as the patient has contractions, and the patient's pulse and blood pressure should be monitored every 30 minutes for the first hour, then hourly for the first 24 hours, then every 4 hours 20 .
Beta agonists-Selective b 2 agonists such as ritodrine and salbutamol with predominantly b 2-receptor effects that relaxes muscle in the uterus have been used in clinical practice for preterm labour since the 1980s 21 . A wide variety of agents have been advocated as suppressing uterine contractions. Currently the most widely used is ritodrine hydrochloride, a beta-agonist activates the enzyme, adenyl cyclase. This in turn leads to the activation of the secondary messenger cyclic adenosine monophosphate and induces myometrial relaxation 22 . The maximum recommended dose is 350g/min. The dose should be kept to the minimum required to inhibit uterine contractions and should be increased at 15 minute intervals until uterine contractions are inhibited, or maternal pulse rate exceeds 140/min, or other side effects become excessive 23 . The recommended infusion rates are given in the table.
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Syringe pump Controlled infusion device Add 3×5ml ampoules ritodrine Add 3×5ml ampoules to 35ml 5% dextrose ritodrine to 500ml 5% dextrose Dose Rate Dose Rate 50 g/min 1 ml/hour 50 g/min 10 ml/hour 100 g/min 2 ml/hour 100 g/min 20 ml/hour 150 g/min 3 ml/hour 150 g/min 30 ml/hour 200 g/min 4 ml/hour 200 g/min 40 ml/hour 250 g/min 5 ml/hour 250 g/min 50 ml/hour 300 g/min 6 ml/hour 300 g/min 60 ml/hour 350 g/min 7 ml/hour 350 g/min 70 ml/hour
Recently an alternative regimen, which uses a 200µg/ min loading dose until tocolysis is reached followed by a reducing dosage infusion, has been suggested 21 .
But these drugs are widely crticised for unpleasant and even fatal maternal side effects. The maternal adverse effects are tachycardia, arrythmia, dyspnoea, hypokalemia, hyperglycemia, and chest pain, hypotension, pulmonary oedema and rarely death. The ritodrine is also associated with hallucination and antidiuresis [24] [25] [26] . Therefore obstetrician need to be very careful about -b agonists while treating PTL . Twin Pregnancy or pregnancy with diabetes and arrythmia are contraindicated for these tocolytics . Specially concomitant use of steroid and beta agonists need extreme caution as pulmonary oedema may kill the patient. Although they have been shown to delay delivery, beta agonists have not been shown to improve perinatal outcome. Though the efficacy of b -agonists in postponement of PTL is similar to the other tocolytics and placebo but they are no longer seem the best choice and gradually its popularity is declining. Several RCT trials showed that ritodrine or b agonists should not be the 1 st line of tocolytic 27 .
The beta-3 adrenoreceptor agonist BRL 37344 induced relaxation of human myometrial contractions with similar potency to that of the most commonly used tocolytic agent ritodrine. This raises the possibility that the novel beta-3 adrenoreceptor agonists may have potential as therapeutic agents for human preterm labour. In view of their reported reduced cardiovascular side effects their potential clinical use requires further evaluation 14 .
Magnesium sulfate -The relaxant effect of Magnesium sulphate in vitro and in vivo on human uterine contractility has been widely reported. As magnesium is a calcium antagonist, it decreases calcium intracellular concentration and inhibits contraction process 28 . It is an important tocolytic act by inhibiting myocin light chain and thereby suppressing the uterine contraction. Magnesium sulfate is also commonly used, better tolerated, but the patient must be monitored for toxic effects, such as respiratory depression or even cardiac arrest, which can occur at super therapeutic levels. Common maternal side effects include flushing, nausea, headache, drowsiness, and blurred vision. Magnesium crosses the placenta and can cause respiratory and motor depression of the neonate.
Magnesium sulfate is usually given through a vein (intravenously) until contractions have slowed and the mother's cervix has stopped thinning (effacing) or opening (dilating) 28 . The usual dose is 4-8 gm iv slowly. Numerous RCT have shown that it is effective as other tocolytics as b-agonists, CCB, and atosiban. But again the safety profile is argued everywhere. The most disadvantage is it needs intravenous adminstration and it produces hot flushes, lethargy, headache, diplopia, dry mouth, and rarely cardio respiratory arrest.
Oxytocin Receptor Antagonists -These agents are in competition with the myometrial and decidual oxytocin receptors. The only drug used in clinical practice is Atosiban. It blocks in a reversive manner the intracytoplasmic calcium release associated with contractions and down regulates prostaglandin synthesis. This drug is FDA approved and when compared to the other tocolytics and placebo it is proved to be very effective tocolytic. Atosiban is given 7.5 mg/ml solution for injection, immediately followed by a continuous high dose infusion (loading infusion 300 micrograms/min) of Atosiban 7.5 mg/ml concentrate for solution for infusion during three hours, followed by a lower dose of Atosiban 7.5 mg/ ml concentrate for solution for infusion (subsequent infusion 100 micrograms/min) up to 45 hours. The duration of the treatment should not exceed 48 hours. The total dose given during a full course of therapy should preferably not exceed 330 mg of the active substance 24 .
Prostaglandin-Synthetase Inhibitors -Prostaglandinsynthetase or cyclooxygenase (COX) isoforms COX-1 and -2 are essential enzymes for converting arachidonic acid to prostaglandins. Prostaglandins are well-known uterine contraction inducer by enhancing myometrial gap junction and increasing intracellular calcium concentration 7, 14 . Indomethacin a nonspecific COX-2 inhibitor, has been reported in studies and in a recent meta-analysis to be an efficient tocolytic drug compared to placebo, significantly delaying preterm delivery 29 . It can be administrated rectally or orally. Its use should be restricted in duration and limited to pregnancies below 32 weeks because of fetal ductus arteriosus closure risk and decreased urine production responsible for oligohydramnios 29 . These treatments also have maternal side effects including gastric ulcer or asthma recurrence (NASAID-indomethacin has also been shown to have efficacy similar to that of ritodrine). It is associated with infrequent maternal side effects, but it readily crosses the placenta and can cause oligohydramnios if used for more than 48 hours. Usually the amniotic fluid reaccumulates, but persistent fetal anuria, renal microcystic lesions, and neonatal death have been reported.
Discussion
The short term goal of tocolysis is to continue pregnancy for 48 hours and long term goal to continue pregnancy beyond 34-37 weeks at which point tocolysis can be discontinued for diminished chance of fetal morbidity and mortality. Since none of the existing treatments truly arrest the process for more than a few days, and on the assumption that they are similar in severity and frequency of side-effects, the most important outcome measure can be argued to be admission rates to the neonatal intensive-care unit.
As a proxy for serious morbidity, as well as for cost, admissions to the intensive-care unit represent a straightforward measure of the value of a tocolytic agent. In this study, the nifedipine-treated group had significantly fewer admissions than did the ritodrinetreated group.
Although Nifedipine can cross the placenta, most of the RCT trials and Cochrane systemic review showed that CCB are effective, cheap, easily adminstrable with fewer side effects. On the other hand Atosiban though not available in our country has better maternal safety but not devoid of foetal adverse outcome even it is been associated with perinatal death 30 . Moreover it is very expensive. Recent study by ABRAHAM et al proved that Nifedipine could be a reasonable 1 st choice as tocolytic because it does not carry any foetal risks unlike indomethacin or b agonists 30 . Depending on the tocolytic used the mother or fetus may require monitoring, as for instance blood pressure monitoring when nifedipine is used as it reduces blood pressure. In any case the risk of preterm labor alone justifies hospitalization. 11 . So neonatologist must aware of the tocolytics used for PTL and they should apprehend the situation.
Moreover Mgso 4 needs extensive monitoring specially serum magnesium which is not always available. Magso 4 has adverse fetal effect like respiratory depression, hypotonia, deminarilasion 15 . So intravenous route, maternal and foetal adverse effects and necessity of strict monitoring for MgSO4 make it unpopular. Calcium-channel blockers and an oxytocin antagonist can delay delivery by 2-7 days 13 . Otherwise, tocolysis is rarely successful beyond 24-48 hours because current medication do not alter the fundamentals of labor activation 14 . However, just gaining 48 hours is sufficient to allow the pregnant women to be transferred to a center specialized for management of preterm deliveries and give administered corticosteroids the possibility to reduce neonatal organ immaturity.
RCT trial of atosiban with B-agonists showed that both of them are equally effective as tocolytics and there is no significant difference in neonatal morbidities and mortalities. Unlike b-agonists Atosiban has less maternal side effects and appeared superior to b-agonists & Mgso 4 .
The consensus is Atosiban & nifedipine appear preferable than any other tocolytics as they have Bangladesh J Obstet Gynaecol Vol. 27, No. 1 fewer side effects, but 3RCT trials showed that Atosiban has no better efficacy than b-agonists and CCB rather Atosiban is associated with few perinatal death 4 . Indomethacin, is often used as tocoyltic but they are associeted with severe neonatal side effects particularly anuria, oliguria, necrotising colitis and closure of ductus arteriosus. Therefore again they are not being used as primary tocolytic.
Conclusion:
Ideal tocolytics should not do harm to foetus and to mother & should be very easily adminstrable. They should be very cheap and their efficacy should be almost 100 % but unfortunately none of the tocolytics fulfill these criterias . Nevertheless upto now Nifedipine is found to be preferable for our country.
